Laboratory diagnostics of inherited platelet disorders.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 24698825)

Published in Clin Chem Lab Med on August 01, 2014

Authors

Cecilia Carubbi, Elena Masselli, Antonio Nouvenne, Domenico Russo, Daniela Galli, Prisco Mirandola, Giuliana Gobbi, Marco Vitale

Articles by these authors

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med (2002) 8.86

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med (1994) 3.26

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood (2013) 2.53

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med (2016) 2.36

Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis (2013) 2.27

Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ Res (2006) 1.96

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood (2009) 1.90

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood (2009) 1.76

Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med (2011) 1.75

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica (2002) 1.72

NK cells and cancer. J Immunol (2007) 1.56

Progression of cardiac valve calcification and decline of renal function in CKD patients. J Nephrol (2013) 1.42

A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther (2003) 1.41

Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol (2012) 1.38

Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol (2007) 1.28

Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. J Invest Dermatol (2002) 1.27

HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res (2005) 1.22

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res (2003) 1.19

Long-term treatment with potassium citrate and renal stones in medullary sponge kidney. Clin J Am Soc Nephrol (2010) 1.18

Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood (2004) 1.17

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) sequentially upregulates nitric oxide and prostanoid production in primary human endothelial cells. Circ Res (2003) 1.17

Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell Physiol (2007) 1.15

Hydrogen sulfide prevents apoptosis of human PMN via inhibition of p38 and caspase 3. Lab Invest (2006) 1.14

A3 adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol Chem (2005) 1.13

Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer (2013) 1.09

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood (2004) 1.09

Abnormal VWF modifies megakaryocytopoiesis: studies of platelets and megakaryocyte cultures from patients with von Willebrand disease type 2B. Blood (2010) 1.08

Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int J Oncol (2006) 1.04

TGFbeta/BMP activate the smooth muscle/bone differentiation programs in mesoangioblasts. J Cell Sci (2004) 1.03

Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol (2006) 1.02

A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter (2007) 1.01

Timing and expression level of protein kinase C epsilon regulate the megakaryocytic differentiation of human CD34 cells. Stem Cells (2007) 1.00

Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol (2005) 1.00

Dialysate bath and QTc interval in patients on chronic maintenance hemodialysis: pilot study of single dialysis effects. J Nephrol (2012) 0.99

Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol (2007) 0.99

miR669a and miR669q prevent skeletal muscle differentiation in postnatal cardiac progenitors. J Cell Biol (2011) 0.99

IGF-1, the cross road of the nutritional, inflammatory and hormonal pathways to frailty. Nutrients (2013) 0.99

NK-active cytokines IL-2, IL-12, and IL-15 selectively modulate specific protein kinase C (PKC) isoforms in primary human NK cells. Anat Rec (2002) 0.98

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res (2008) 0.97

Rituximab for the treatment of type II mixed cryoglobulinemia. Arthritis Rheum (2002) 0.96

Neutrophil gelatinase-associated lipocalin in cancer. Adv Clin Chem (2014) 0.96

Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood (2002) 0.95

Chronic kidney disease and cardiovascular complications. Heart Fail Rev (2015) 0.95

SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood (2011) 0.94

Vaccination with filamentous bacteriophages targeting DEC-205 induces DC maturation and potent anti-tumor T-cell responses in the absence of adjuvants. Eur J Immunol (2011) 0.94

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol (2006) 0.94

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood (2002) 0.92

Reducing unnecessary hospital days to improve quality of care through physician accountability: a cluster randomised trial. BMC Health Serv Res (2013) 0.92

The dominant negative β isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood (2011) 0.92

Bone disease in medullary sponge kidney and effect of potassium citrate treatment. Clin J Am Soc Nephrol (2009) 0.92

Protein kinase C ε in hematopoiesis: conductor or selector? Semin Thromb Hemost (2012) 0.91

A(2B) and A(3) adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. Neoplasia (2009) 0.91

Lifestyle recommendations to reduce the risk of kidney stones. Urol Clin North Am (2011) 0.91

Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. Int J Oncol (2004) 0.91

Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol (2008) 0.91

Glycosphingolipids: synthesis and functions. FEBS J (2013) 0.91

Exogenous hydrogen sulfide induces functional inhibition and cell death of cytotoxic lymphocytes subsets. J Cell Physiol (2007) 0.90

Noradrenergic and cholinergic innervation of the bone marrow. Int J Mol Med (2002) 0.90

Inositides in the nucleus: regulation of nuclear PI-PLCbeta1. Adv Enzyme Regul (2002) 0.90

Reversine-treated fibroblasts acquire myogenic competence in vitro and in regenerating skeletal muscle. Cell Death Differ (2006) 0.90

Dietary habits in women with recurrent idiopathic calcium nephrolithiasis. J Transl Med (2012) 0.90

Phorbol ester-induced PKCepsilon down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation. Blood (2008) 0.90

A3 adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. Neoplasia (2005) 0.90

Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol (2014) 0.89

Concentrated urine and diluted urine: the effects of citrate and magnesium on the crystallization of calcium oxalate induced in vitro by an oxalate load. Urol Res (2006) 0.89

PKCepsilon controls protection against TRAIL in erythroid progenitors. Blood (2005) 0.89

Acute effects of very-low-protein diet on FGF23 levels: a randomized study. Clin J Am Soc Nephrol (2012) 0.89

Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation (2014) 0.88

Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. Br J Haematol (2002) 0.88

Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk Res (2010) 0.87

Differential activation of signaling pathways by low-osmolar and iso-osmolar radiocontrast agents in human renal tubular cells. J Cell Biochem (2014) 0.87

Multiplexing and demultiplexing logic functions for computing signal processing tasks in synthetic biology. Biotechnol J (2011) 0.87

Polymorphisms at the regulatory regions of the CASR gene influence stone risk in primary hyperparathyroidism. Eur J Endocrinol (2010) 0.87

In vitro calcified matrix deposition by human osteoblasts onto a zinc-containing bioactive glass. Eur Cell Mater (2011) 0.87

Cannabinoid CB(2) receptor attenuates morphine-induced inflammatory responses in activated microglial cells. Br J Pharmacol (2012) 0.86

Effects of urine dilution on quantity, size and aggregation of calcium oxalate crystals induced in vitro by an oxalate load. Clin Chem Lab Med (2005) 0.86

Ramipril in post-renal transplant erythrocytosis. J Nephrol (2007) 0.86

Calibrated real-time polymerase chain reaction for specific quantitation of HHV-6A and HHV-6B in clinical samples. J Virol Methods (2013) 0.86

Identification of novel linear megaplasmids carrying a ß-lactamase gene in neurotoxigenic Clostridium butyricum type E strains. PLoS One (2011) 0.85

Low-amplitude high frequency vibration down-regulates myostatin and atrogin-1 expression, two components of the atrophy pathway in muscle cells. J Tissue Eng Regen Med (2012) 0.84

Decreased transcriptional activity of calcium-sensing receptor gene promoter 1 is associated with calcium nephrolithiasis. J Clin Endocrinol Metab (2013) 0.84

Reproducible noninvasive method for evaluation of glenoid bone loss by multiplanar reconstruction curved computed tomographic imaging using a cadaveric model. Arthroscopy (2013) 0.84

Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients. Nephrol Dial Transplant (2009) 0.84